Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share (PRLD)

Q: What does CUSIP 74065P101 represent in this 13F holders report?

CUSIP 74065P101 is the security identifier for PRLD - Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share used to aggregate holder disclosures.

Q: How many institutions held PRLD - Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share in Q1 2026?

15 institutional investors reported PRLD - Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share for Q1 2026. Use the holders table for investor-level position and value details.

CUSIP: 74065P101

Q1 2026 13F Holders as of 31 Mar 2026

Type / Class: Equity / Common Stock, $0.0001 par value per share
Shares outstanding: 65,427,364
Total 13F shares: 1,814,613
Share change: +81,257
Total reported value: $6,206,478
Price per share: $3.42
Number of holders: 15
Value change: +$360,710
Number of buys: 6
Number of sells: 4

Quarterly Holders Quick Answers

What is CUSIP 74065P101?
CUSIP 74065P101 identifies PRLD - Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Previous quarter: Q4 2025

Recent filing periods for CUSIP 74065P101:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of PRLD - Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
ORBIMED ADVISORS LLC	13F	Company	17%	10,909,256	$31,636,842	—	31 Dec 2025	13F
BAKER BROS. ADVISORS LP	13F	Company	15%	10,123,824	$29,359,090	—	31 Dec 2025	13F
Vaddi Krishna	13D/G 3/4/5	CEO, Director	13%	6,745,647	$19,562,376	+$1,008,643	31 Dec 2025	13D/G 3/4/5
INCYTE CORP	13D/G	—	9.9%	4,372,124	$6,295,859	$0	03 Nov 2025	13D/G
VANGUARD GROUP INC	13F	Company	2.2%	1,413,986	$4,100,559	—	31 Dec 2025	13F
Kynam Capital Management, LP	13F	Company	1.2%	788,867	$2,287,714	—	31 Dec 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	1.2%	788,695	$2,287,216	—	31 Dec 2025	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	1.2%	755,956	$2,193,000	—	31 Dec 2025	13F
ACADIAN ASSET MANAGEMENT LLC	13F	Company	0.82%	535,703	$1,551,000	—	31 Dec 2025	13F
MORGAN STANLEY	13F	Company	0.51%	334,916	$971,257	—	31 Dec 2025	13F
MARSHALL WACE, LLP	13F	Company	0.42%	273,883	$794,260	—	31 Dec 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.42%	272,886	$791,502	—	31 Dec 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.41%	271,300	$786,770	—	31 Dec 2025	13F
BlackRock, Inc.	13F	Company	0.41%	266,280	$772,212	—	31 Dec 2025	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.36%	237,300	$688,170	—	31 Dec 2025	13F
TD ASSET MANAGEMENT INC	13F	Company	0.25%	160,652	$465,891	—	31 Dec 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.23%	150,997	$437,891	—	31 Dec 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.21%	135,909	$394,136	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	0.19%	127,292	$369,147	—	31 Dec 2025	13F
SPHERA FUNDS MANAGEMENT LTD.	13F	Company	0.19%	122,752	$355,981	—	31 Dec 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.18%	117,477	$340,683	—	31 Dec 2025	13F
Andrew Combs	3/4/5	Chief Chemistry Officer	— mixed-class rows	710,123 mixed-class rows	$332,485	—	04 Feb 2026	3/4/5
JANE STREET GROUP, LLC	13F	Company	0.17%	111,040	$322,016	—	31 Dec 2025	13F
Sean P. Brusky	3/4/5	Chief Business Officer	0.15%	100,000	$278,000	—	05 Mar 2026	3/4/5
OMERS ADMINISTRATION Corp	13F	Company	0.11%	73,000	$211,700	—	31 Dec 2025	13F
MANUFACTURERS LIFE INSURANCE COMPANY, THE	13F	Company	0.11%	70,546	$200,428	—	31 Dec 2025	13F
Point72 Asset Management, L.P.	13F	Company	0.09%	59,168	$171,587	—	31 Dec 2025	13F
Laurent Chardonnet	3/4/5	Chief Financial Officer	— mixed-class rows	192,165 mixed-class rows	$158,962	—	01 Mar 2024	3/4/5
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.08%	53,500	$155,150	—	31 Dec 2025	13F
Jane Huang	3/4/5	President, CMO	— mixed-class rows	305,667 mixed-class rows	$153,736	—	04 Oct 2025	3/4/5
XTX Topco Ltd	13F	Company	0.08%	50,159	$145,461	—	31 Dec 2025	13F
NORTHERN TRUST CORP	13F	Company	0.08%	50,120	$145,348	—	31 Dec 2025	13F
Focus Partners Wealth	13F	Company	0.08%	50,007	$145,020	—	31 Dec 2025	13F
Connor, Clark & Lunn Investment Management Ltd.	13F	Company	0.07%	46,090	$133,661	—	31 Dec 2025	13F
Cerity Partners LLC	13F	Company	0.05%	32,953	$95,564	—	31 Dec 2025	13F
Qube Research & Technologies Ltd	13F	Company	0.03%	21,551	$62,498	—	31 Dec 2025	13F
PRUDENTIAL FINANCIAL INC	13F	Company	0.02%	15,520	$45,008	—	31 Dec 2025	13F
HSBC HOLDINGS PLC	13F	Company	0.02%	13,652	$39,454	—	31 Dec 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.01%	9,808	$28,443	—	31 Dec 2025	13F
BARCLAYS PLC	13F	Company	0.01%	8,602	$24,946	—	31 Dec 2025	13F
FMR LLC	13F	Company	0.01%	6,152	$17,841	—	31 Dec 2025	13F
Christopher Pierce	3/4/5	EVP and Chief of Business Oper	— mixed-class rows	211,546 mixed-class rows	$14,138	—	02 Sep 2021	3/4/5
SBI Securities Co., Ltd.	13F	Company	0%	2,741	$7,949	—	31 Dec 2025	13F
CALDWELL SUTTER CAPITAL, INC.	13F	Company	0%	2,000	$5,800	—	31 Dec 2025	13F
UBS Group AG	13F	Company	0%	1,857	$5,385	—	31 Dec 2025	13F
ROYAL BANK OF CANADA	13F	Company	0%	1,699	$5,000	—	31 Dec 2025	13F
NISA INVESTMENT ADVISORS, LLC	13F	Company	0%	1,634	$4,739	—	31 Dec 2025	13F
PNC FINANCIAL SERVICES GROUP, INC.	13F	Company	0%	1,171	$3,396	—	31 Dec 2025	13F
CWM, LLC	13F	Company	0%	692	$2,000	—	31 Dec 2025	13F
GROUP ONE TRADING LLC	13F	Company	0%	500	$1,450	—	31 Dec 2025	13F

Institutional Holders of Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share (PRLD) as of Q1 2026

As of 31 Mar 2026, Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share (PRLD) was held by 15 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 1,814,613 shares. The largest 10 holders included VANGUARD CAPITAL MANAGEMENT LLC, JANE STREET GROUP, LLC, VANGUARD FIDUCIARY TRUST CO, Connor, Clark & Lunn Investment Management Ltd., UBS Group AG, DIMENSIONAL FUND ADVISORS LP, HSBC HOLDINGS PLC, Vanguard Global Advisers, LLC, SBI Securities Co., Ltd., and NISA INVESTMENT ADVISORS, LLC. This page lists 15 institutional shareholders reporting positions in this security for the Q1 2026 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2026 vs Q4 2025 Across Filers

Q4 2025 holders

Q1 2026 holders

Holder diff

-33

Investor	Q4 2025 Shares	Q1 2026 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q1 2026 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.